FT-104

FT-104 is a synthetic cannabinoid that is structurally similar to THC, the active ingredient in cannabis. It was first synthesized in 2020 and is currently being researched for its potential therapeutic uses.

Chemistry

FT-104 is a G protein-coupled receptor agonist that binds to the same receptors as THC. It is a full agonist of the CB1 receptor, which is primarily found in the brain, and a partial agonist of the CB2 receptor, which is found in the immune system and peripheral tissues. The chemical structure of FT-104 is similar to that of THC, but it has a fluorine atom at the 9-position, which may contribute to its increased potency.

Pharmacology

The pharmacological effects of FT-104 are not fully understood, as it is a relatively new compound and research is ongoing. However, preliminary studies suggest that it may have similar effects to THC, including pain relief, anti-inflammatory effects, and potential anti-cancer properties. It is also believed to have a higher potency and longer duration of action than THC.

Potential Therapeutic Uses

Research into the therapeutic uses of FT-104 is still in the early stages. However, due to its similarity to THC, it is believed that it may have potential in the treatment of conditions such as chronic pain, inflammation, and certain types of cancer. Further research is needed to fully understand the potential benefits and risks of FT-104.

Legal Status

As of 2021, FT-104 is not specifically listed in any international drug control treaties. However, due to its structural similarity to THC, it may be considered a controlled substance in some jurisdictions under analogue laws.

See Also

• Cannabinoid
• THC
• G protein-coupled receptor
• CB1 receptor
• CB2 receptor